GetTopicDetailResponse(id=0e5310542d9, topicName=KN046, introduction=KN046, content=null, image=null, comments=2, allHits=1437, url=https://h5.medsci.cn/topic?id=10542, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=103595, tagList=[TagDto(tagId=103595, tagName=KN046)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2257292, encodeId=f615225e292ca, content=<a href='/topic/show?id=0e5310542d9' target=_blank style='color:#2F92EE;'>#KN046#</a> <a href='/topic/show?id=7c7f12368262' target=_blank style='color:#2F92EE;'>#KN026#</a> <a href='/topic/show?id=b867125352a8' target=_blank style='color:#2F92EE;'>#HER2陽性非乳腺癌#</a>, objectTitle=STTT | KN026聯(lián)合KN046在HER2陽性非乳腺癌中的療效和安全性分析：一項(xiàng)Ib期和II期的綜合分析, objectType=article, longId=868330, objectId=171d86833057, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20250321/1742563292702_6145188.png, objectUrl=/article/show_article.do?id=171d86833057, replyNumber=0, likeNumber=34, createdTime=2025-03-22, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陜西省, moduleDTOList=[ModuleDTO(moduleId=171d86833057, moduleTitle=STTT | KN026聯(lián)合KN046在HER2陽性非乳腺癌中的療效和安全性分析：一項(xiàng)Ib期和II期的綜合分析, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=171d86833057)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2186208, encodeId=258221862089b, content=<a href='/topic/show?id=33771982175' target=_blank style='color:#2F92EE;'>#三陰性乳腺癌#</a> <a href='/topic/show?id=2916e177389' target=_blank style='color:#2F92EE;'>#白蛋白結(jié)合型紫杉醇#</a> <a href='/topic/show?id=0e5310542d9' target=_blank style='color:#2F92EE;'>#KN046#</a>, objectTitle=Nat. Commun：抗PD-L1/CTLA-4雙特異性抗體KN046聯(lián)合白蛋白結(jié)合型紫杉醇一線治療轉(zhuǎn)移性三陰性乳腺癌：多中心II期試驗(yàn), objectType=article, longId=812453, objectId=d158812453bf, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240205/1707138204572_6145188.png, objectUrl=/article/show_article.do?id=d158812453bf, replyNumber=0, likeNumber=141, createdTime=2024-02-06, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=d158812453bf, moduleTitle=Nat. Commun：抗PD-L1/CTLA-4雙特異性抗體KN046聯(lián)合白蛋白結(jié)合型紫杉醇一線治療轉(zhuǎn)移性三陰性乳腺癌：多中心II期試驗(yàn), moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=d158812453bf)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2040434, encodeId=10d12040434e2, content=<a href='/topic/show?id=0e5310542d9' target=_blank style='color:#2F92EE;'>#KN046#</a>, objectTitle=康寧杰瑞與應(yīng)世生物宣布合作開展，KN046聯(lián)合IN10018的臨床研究, objectType=article, longId=194632, objectId=2889194632a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2889194632a8, replyNumber=0, likeNumber=90, createdTime=2021-03-01, rootId=0, userName=yilong5287542, userId=87f580, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2889194632a8, moduleTitle=康寧杰瑞與應(yīng)世生物宣布合作開展，KN046聯(lián)合IN10018的臨床研究, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=2889194632a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2040435, encodeId=4c0f2040435c7, content=<a href='/topic/show?id=0e5310542d9' target=_blank style='color:#2F92EE;'>#KN046#</a>, objectTitle=雙特異性抗體KN026與KN046聯(lián)合療法獲美國FDA孤兒藥資格認(rèn)定，用于治療胃癌及胃食管連接部癌, objectType=article, longId=204839, objectId=18592048396e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18592048396e, replyNumber=0, likeNumber=82, createdTime=2021-11-21, rootId=0, userName=yilong5287542, userId=87f580, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18592048396e, moduleTitle=雙特異性抗體KN026與KN046聯(lián)合療法獲美國FDA孤兒藥資格認(rèn)定，用于治療胃癌及胃食管連接部癌, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=18592048396e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
